Alcatel-Lucent (Euronext Paris and NYSE: ALU) is helping operators of 4G mobile broadband networks create a new conversation experience for their subscribers by introducing a technology innovation that makes it easy to switch between voice and video-calling, instant messaging and group calling and across a variety of devices – smartphone, tablet or PC – at the touch of a button.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52409-alcatel-lucent-connecting-video-made-simple-4g-mobile-broadband-solution
Alcatel-Lucent (Euronext Paris and NYSE: ALU) today announced a major advance to its global leadership in 100G optical networking by introducing a breakthrough in single-carrier coherent technology that will extend optical signals over distances far greater than has been possible before, even over poor quality fiber. This latest addition to the company’s portfolio is designed to enhance the ability of communications service providers to address exploding demand for high-bandwidth services like video and fixed and mobile broadband.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53498-alcatel-lucent-expands-100g
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
Alcatel-Lucent (Euronext Paris and NYSE: ALU) has today launched an extended portfolio of software and services designed to improve the experience that consumers have with their smartphones, tablets and other connected devices.
When consumers buy a new device or service they expect everything will work right from the start and any glitch will be quickly resolved. The expectation is that the focus is on the customer – not just the network.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54399-alcatel-lucent-motive-customer-experience-support-solution
Alcatel-Lucent (Euronext Paris and NYSE: ALU) will hold a live video press conference to announce a groundbreaking innovation in core networking (www.alcatel-lucent.com/rethink-the-core-network) at the company’s annual Technology Symposium 2012 taking place in Santa Clara, California May 22 – 23.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55906-alcatel-lucent-to-unveil-major-breakthrough-innovation-in-core-networking
Alcatel-Lucent (Euronext Paris and NYSE: ALU), is to enter the $4bn-a-year market for Internet core routers, with breakthrough technologies that promise enhanced capacity and connectivity, improved energy consumption and dramatically lower costs for the world’s communication networks.
To view Multimedia News Release, go http://www.multivu.com/mnr/55907-alcatel-lucent-unveils-new-core-router
Coca-Cola Enterprises (NYSE/NYSE Euronext Paris: CCE), which produces, markets and distributes Coca-Cola products in Western Europe, is today announcing two new initiatives aimed at improving recycling behavior and infrastructure, as part of its journey to becoming a low-carbon, zero-waste business. CCE’s sustainability plan commits it to setting the standard for sustainable packaging, achieving zero waste in its own operations and recycling more packaging than it uses.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56620-coca-cola-enterprises-sustainability
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
Nuage Networks™, an Alcatel-Lucent (Euronext Paris and NYSE: ALU) venture focused on software defined networking (SDN) solutions, has today announced an open software-based solution to address the key datacenter network constraints that limit cloud services adoption. The Virtualized Services Platform (VSP) will allow healthcare, banking, utilities and other enterprise market segments, as well as webscale companies – large Internet-based companies – and telecom service providers, to scale their cloud offers and provide instant, secure connectivity to multiple customers.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60963-alcatel-lucent-nuage-networks-virtualized-services-platform-cloud-solution
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
